Benzodeazaoxaflavins as sirtuin inhibitors with antiproliferative properties in cancer stem cells

Journal of Medicinal Chemistry

Volumn 55, Issue 18, 2012, Pages 8193-8197

  Rotili, Dante ^a   Tarantino, Domenico ^a   Carafa, Vincenzo ^b   Paolini, Chantal ^c   Schemies, Jörg ^d   Jung, Manfred ^d   Botta, Giorgia ^a   Di Maro, Salvatore ^e   Novellino, Ettore ^e   Steinkühler, Christian ^c   De Maria, Ruggero ^f   Gallinari, Paola ^c   Altucci, Lucia ^b,g   Mai, Antonello ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Exiris Srl   (Italy)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^g INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

10 PHENYL 9H BENZO[5,6]CHROMENO[2,3 D]PYRIMIDINE 9,11(10H) DIONE; 10 PROPYL 9H BENZO[5,6]CHROMENO[2,3 D]PYRIMIDINE 9,11(10H) DIONE; 3 ETHYL 2H CHROMENO[2,3 D]PYRIMIDINE 2,4(3H) DIONE; BENZODEAZAOXAFLAVIN DERIVATIVE; ENZYME INHIBITOR; QUERCETIN; SIRTUIN 1; SIRTUIN 2; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER RECURRENCE; CANCER STEM CELL; CARCINOGENESIS; COLORECTAL CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FLAVINS; HISTONE DEACETYLASE INHIBITORS; HUMANS; NEOPLASTIC STEM CELLS; SIRTUINS;

EID: 84866849116     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301115r     Document Type: Article

References (25)

1. Haigis, M. C.; Sinclair, D. A. Mammalian sirtuins: biological insights and disease relevance Annu. Rev. Pathol. 2010, 5, 253-295
2. Guarente, L.; Franklin, H. Epstein Lecture: Sirtuins, Aging, and Medicine N. Engl. J. Med. 2011, 364, 2235-2244
3. Mostoslavsky, R.; Esteller, M.; Vaquero, A. At the crossroad of lifespan, calorie restriction, chromatin and disease: meeting on sirtuins Cell Cycle 2010, 9, 1907-1912
4. Peng, C.; Lu, Z.; Xie, Z.; Cheng, Z.; Chen, Y.; Tan, M.; Luo, H.; Zhang, Y.; He, W.; Yang, K.; Zwaans, B. M.; Tishkoff, D.; Ho, L.; Lombard, D.; He, T. C.; Dai, J.; Verdin, E.; Ye, Y.; Zhao, Y. The first identification of lysine malonylation substrates and its regulatory enzyme Mol. Cell. Proteomics 2011, 10, M111 012658
5. Cen, Y. Sirtuins inhibitors: the approach to affinity and selectivity Biochim. Biophys. Acta 2010, 1804, 1635-1644
6. Fraga, M. F.; Agrelo, R.; Esteller, M. Cross-talk between aging and cancer: the epigenetic language Ann. N. Y. Acad. Sci. 2007, 1100, 60-74
7. Ota, H.; Tokunaga, E.; Chang, K.; Hikasa, M.; Iijima, K.; Eto, M.; Kozaki, K.; Akishita, M.; Ouchi, Y.; Kaneki, M. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells Oncogene 2006, 25, 176-185
8. Heltweg, B.; Gatbonton, T.; Schuler, A. D.; Posakony, J.; Li, H.; Goehle, S.; Kollipara, R.; Depinho, R. A.; Gu, Y.; Simon, J. A.; Bedalov, A. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes Cancer Res. 2006, 66, 4368-4377
9. Lara, E.; Mai, A.; Calvanese, V.; Altucci, L.; Lopez-Nieva, P.; Martinez-Chantar, M. L.; Varela-Rey, M.; Rotili, D.; Nebbioso, A.; Ropero, S.; Montoya, G.; Oyarzabal, J.; Velasco, S.; Serrano, M.; Witt, M.; Villar-Garea, A.; Imhof, A.; Mato, J. M.; Esteller, M.; Fraga, M. F. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect Oncogene 2009, 28, 781-791
10. Lain, S.; Hollick, J. J.; Campbell, J.; Staples, O. D.; Higgins, M.; Aoubala, M.; McCarthy, A.; Appleyard, V.; Murray, K. E.; Baker, L.; Thompson, A.; Mathers, J.; Holland, S. J.; Stark, M. J.; Pass, G.; Woods, J.; Lane, D. P.; Westwood, N. J. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator Cancer Cell 2008, 13, 454-463
11. Li, L.; Wang, L.; Wang, Z.; Ho, Y.; McDonald, T.; Holyoake, T. L.; Chen, W.; Bhatia, R. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib Cancer Cell 2012, 21, 266-81
12. Napper, A. D.; Hixon, J.; McDonagh, T.; Keavey, K.; Pons, J. F.; Barker, J.; Yau, W. T.; Amouzegh, P.; Flegg, A.; Hamelin, E.; Thomas, R. J.; Kates, M.; Jones, S.; Navia, M. A.; Saunders, J. O.; DiStefano, P. S.; Curtis, R. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1 J. Med. Chem. 2005, 48, 8045-8054
13. Solomon, J. M.; Pasupuleti, R.; Xu, L.; McDonagh, T.; Curtis, R.; DiStefano, P. S.; Huber, L. J. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage Mol. Cell. Biol. 2006, 26, 28-38
14. Mai, A.; Massa, S.; Lavu, S.; Pezzi, R.; Simeoni, S.; Ragno, R.; Mariotti, F. R.; Chiani, F.; Camilloni, G.; Sinclair, D. A. Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors J. Med. Chem. 2005, 48, 7789-7795
15. Mai, A.; Valente, S.; Meade, S.; Carafa, V.; Tardugno, M.; Nebbioso, A.; Galmozzi, A.; Mitro, N.; De Fabiani, E.; Altucci, L.; Kazantsev, A. Study of 1,4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors J. Med. Chem. 2009, 52, 5496-5504
16. Pasco, M. Y.; Rotili, D.; Altucci, L.; Farina, F.; Rouleau, G. A.; Mai, A.; Neri, C. Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specific sirtinol analogues J. Med. Chem. 2010, 53, 1407-1411
17. Rotili, D.; Tarantino, D.; Carafa, V.; Lara, E.; Meade, S.; Botta, G.; Nebbioso, A.; Schemies, J.; Jung, M.; Kazantsev, A. G.; Esteller, M.; Fraga, M. F.; Altucci, L.; Mai, A. Identification of tri- and tetracyclic pyrimidinediones as sirtuin inhibitors ChemMedChem 2010, 5, 674-677
18. Rotili, D.; Carafa, V.; Tarantino, D.; Botta, G.; Nebbioso, A.; Altucci, L.; Mai, A. Simplification of the tetracyclic SIRT1-selective inhibitor MC2141: coumarin- and pyrimidine-based SIRT1/2 inhibitors with different selectivity profile Bioorg. Med. Chem. 2011, 19, 3659-3668
19. Orecchia, A.; Scarponi, C.; Di Felice, F.; Cesarini, E.; Avitabile, S.; Mai, A.; Mauro, M. L.; Sirri, V.; Zambruno, G.; Albanesi, C.; Camilloni, G.; Failla, C. M. Sirtinol treatment reduces inflammation in human dermal microvascular endothelial cells PLoS One 2011, 6, e24307
20. Outeiro, T. F.; Kontopoulos, E.; Altmann, S. M.; Kufareva, I.; Strathearn, K. E.; Amore, A. M.; Volk, C. B.; Maxwell, M. M.; Rochet, J. C.; McLean, P. J.; Young, A. B.; Abagyan, R.; Feany, M. B.; Hyman, B. T.; Kazantsev, A. G. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease Science 2007, 317, 516-519
21. Prud'homme, G. J. Cancer stem cells and novel targets for antitumor strategies Curr. Pharm. Des. 2012, 18, 2838-2849
22. Alison, M. R.; Lim, S. M.; Nicholson, L. J. Cancer stem cells: problems for therapy? J. Pathol. 2011, 223, 147-161
23. Hauser, A. T.; Jung, M. Assays for histone deacetylases Curr. Top. Med. Chem. 2009, 9, 227-234
24. Ricci-Vitiani, L.; Lombardi, D. G.; Pilozzi, E.; Biffoni, M.; Todaro, M.; Peschle, C.; De Maria, R. Identification and expansion of human colon-cancer-initiating cells Nature 2007, 445, 111-115
25. Ricci-Vitiani, L.; Pallini, R.; Larocca, L. M.; Lombardi, D. G.; Signore, M.; Pierconti, F.; Petrucci, G.; Montano, N.; Maira, G.; De Maria, R. Mesenchymal differentiation of glioblastoma stem cells Cell Death Differ. 2008, 15, 1491-1498